Navigation Links
Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
Date:9/1/2011

NEW YORK, Sept. 1, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) reported top-line results from the metastatic colorectal (adenocarcinoma) cohort of the Phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancer.  The Company also confirmed plans to initiate a new Phase II single-arm study in the second half of 2012.  The new study is intended to evaluate the efficacy of Delcath's chemosaturation system and its next-generation high efficiency filter in patients with colorectal cancer that is metastatic to the liver and is refractory to first line systemic chemotherapy.

The recently completed Phase II study, conducted at the National Cancer Institute (NCI) in the U.S., included four patient cohorts: hepatobiliary cancers, and metastatic cancers of neuroendocrine, ocular or cutaneous melanoma, and colorectal (adenocarcinoma) origins.  Sixteen patients with very late stage colorectal cancer liver metastases were recruited into this arm.  The predominant accrual of very late stage patients reflects the changing referral and treatment patterns at the NCI at the time that this study was conducted, but it was not a design feature of the study.  No significant responses were noted among these patients as they had been heavily pre-treated with numerous chemotherapeutic and regional modalities that, along with anatomical and disease-related factors in a few, prevented sufficient melphalan exposure. The safety profile of the chemosaturation system was consistent with that previously reported for the Company's Phase 3 melanoma trial.

"While the efficacy signal from this study was inconclusive due to the factors mentioned above, we believe there is solid clinical and scientific justification to conduct a new Phase II trial in a well-defined metastatic colorectal ("mCRC
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
2. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
3. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
4. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
5. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
6. Delcath on Preliminary List of Additions to Russell Microcap® Index
7. Delcath to Present at the JMP Securities Research Conference
8. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
9. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
10. Delcath to Update Investors on FDA Meeting
11. Delcath Expands Board of Directors With Appointment of Gabriel Leung
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014  Boehringer Ingelheim today announced that ... for review the New Drug Application (NDA) for ... delivered via the Respimat ® inhaler for ... of airflow obstruction in patients with chronic obstructive ... Tiotropium + olodaterol FDC will not be indicated ...
(Date:8/19/2014)... -- Cardiva Medical, Inc. announced today that it has closed ... 3 private equity financing and a $12.5 million senior ... the proceeds of the Series 3 private equity financing ... VASCADE® Vascular Closure System in the United ... 3 private equity financing was a new investor, Canepa ...
(Date:8/19/2014)... Aug. 19, 2014  Sequence, Inc., an industry leader in ... and medical device manufacturers is opening a third office location ... , as a result of demand by clients to ... opened this month, allows Sequence to better serve new and ... St. Louis office provides Sequence a hub ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2Quality and Compliance Solutions Provider Announces Opening of St. Louis, Missouri Office 2
... FRANCISCO, Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, ... from ongoing clinical,studies of SNS-595 and SNS-032 at ... being held June 7-10, 2007 in Vienna,Austria. , ... Phase 1 clinical trial of SNS-595 in acute ...
... Zurich, June 1, 2007-Cytos Biotechnology AG is ... presentations of its novel,immunotherapeutic CYT003-QbG10 to treat ... were obtained,and will be presented in different ... Academy of Allergology and Clinical Immunology,(EAACI), taking ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007 2
(Date:8/20/2014)... August 20, 2014 BuyCheapTicketsToEvents.com is ... wide selection of tickets to many events. Cheap NHL hockey ... begin in September. , Hockey fans are enthusiastic about their ... tickets for games. Now is the time to acquire 2014 ... in mere months. There will be a great deal of ...
(Date:8/20/2014)... people grow older, they often have difficulty falling asleep ... in the morning. In individuals with Alzheimer,s disease, this ... especially pronounced, often leading to nighttime confusion and wandering. ... Israel Deaconess Medical Center (BIDMC) and the University of ... more fragmented with age. Reported online today in the ...
(Date:8/20/2014)... Mixberry Media announced today its new integrated ... a new source of revenue. , The innovative experience ... a narration of their favorite news and articles using ... Users can now multitask: read/write email, drink coffee, get ... , Mixberry Media’s service converts news and ...
(Date:8/20/2014)... Riverside Health System is pleased to ... its Warsaw Medical Arts team earlier this year, bringing ... is accepting new patients. , Dameron, a 2009 graduate ... residency at the Mountain Area Health Education Center in ... really like the rural aspect of [Tappahannock],” Dameron said ...
(Date:8/19/2014)... As moms and dads prepare their children to go ... normal routine of dropping their little ones off at daycare ... encourages them to use the opportunity to implement a ... Yarker explains, “Kids have small tummies, short attention spans, and ... food handouts, use snack time as another daily opportunity to ...
Breaking Medicine News(10 mins):Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3
... , NEW YORK, Sept. 21 ... the validity of two Minerva Industries, Inc. patents for mobile ... of new evidence which can show Eli Lilly & Company,s ... counsel. The discovery of this patent validity evidence can impact ...
... , ST. LOUIS, Sept. 21 ... Perrigo Company (Nasdaq: PRGO ) of KV,s first-to-file Paragraph ... Drug Administration for a generic equivalent version of GlaxoSmithKline,s Duac(R) gel. ... transaction, KV will receive $14 million from Perrigo at closing and ...
... WASHINGTON, Sept. 21 /EIN News/ According to the Web site ... the Clinton administration Philip Morris "worked off-the-record with . . . ... have been partly funded by a huge increase in tobacco taxes. ... the term "death panels" used by anti-healthcare reform activists determined to ...
... By 2050, 115 million people may suffer from dementia ... Alzheimer,s disease is accelerating at a rapid pace, and by ... from dementia -- a 10 percent increase since 2005, ... double every 20 years, reaching 65.7 million in 2030 and ...
... , , FORT ... Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that ... or dairy in their diet as a way to manage their ... have lactose intolerance worry the condition keeps them from consuming important ...
... , BALTIMORE, Sept. 21 A new ... the recession is contributing to acute, or short-term, physical pain ... Pain Awareness Month, 68 percent of people who experienced acute ... the past year said that the recession caused, increased or ...
Cached Medicine News:Health News:Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 2Health News:Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 3Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 2Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 3Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 4Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 5Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 6Health News:'Death Panel' Inventor & Critic of Healthcare Reform Betsy McCaughey 'Has Close Ties' to Philip Morris; Healthcare Industry Today Offers Complete Coverage 2Health News:Alzheimer's Soars, Global Focus Needed: Study 2Health News:Alzheimer's Soars, Global Focus Needed: Study 3Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 2Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 3Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 4Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 2Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 3Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 4
... A lower cost alternative to Equalizers, the patented ... between two different vessel configurations. With the push ... be quickly and easily adjusted for test tubes ... Ergonomic Design for Unparalleled Comfort Pick one ...
... 384 Well Plate Capability The Equalizer ... original Equalizerexpandable and equal tip spacing, choice of ... capabilities. In addition, this model allows you to ... loading and accessing many gels and for use ...
... The Equalizer With 384 Well Plate Capability ... revolutionary features of the original Equalizerexpandable and equal ... components, and in-lab calibration capabilities. In addition, this ... down to 4.5mm for loading and accessing many ...
... Equally Spaced, Expandable, Multichannel Pipettor ... pipettors and instantly boosts productivity with an ... the simple adjustment of a slide rod. ... transfer of liquids between vessels with different ...
Medicine Products: